Medicare Enrolled
Dr. Raymond Smith, MD
Hematology & Oncology · Quincy, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Smith from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Smith?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Smith
Dr. Raymond Smith is a hematology & oncology specialist in Quincy, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Smith performed 109,147 Medicare services across 2,270 unique beneficiaries.
Between the years covered by Open Payments, Dr. Smith received a total of $10,437 from 62 pharmaceutical and/or device companies across 596 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Smith is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 10% volume in IL
$10,437 industry payments
Medicare Practice Summary
Medicare Utilization ↗109,147
Medicare services
Top 10% in IL for hematology & oncology
2,270
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,457 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
37,500 | $1 | $4 |
| Pembrolizumab injection (Keytruda) | 20,000 | $43 | $124 |
| Denosumab injection (Prolia/Xgeva) | 12,000 | $18 | $54 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,200 | $0 | $0 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
6,060 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
5,980 | $2 | $18 |
| Paclitaxel chemotherapy injection | 3,627 | $0 | $2 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
3,530 | $36 | $172 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,804 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,135 | $93 | $286 |
| Injection, granisetron hydrochloride, 100 mcg | 1,010 | $0 | $3 |
| Anti-nausea injection (Aloxi/palonosetron) | 990 | $1 | $14 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
458 | $58 | $194 |
| Injection, leucovorin calcium, per 50 mg | 427 | $3 | $8 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
396 | $83 | $1,239 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
357 | $95 | $506 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
337 | $11 | $77 |
| Injection, potassium chloride, per 2 meq | 325 | $0 | $2 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
316 | $1 | $3 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
270 | $10 | $64 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
242 | $2 | $11 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
213 | $2 | $14 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 209 | $3 | $19 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
204 | $110 | $689 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
198 | $45 | $217 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
168 | $21 | $121 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
146 | $21 | $118 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
135 | $6 | $79 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
122 | $47 | $245 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
101 | $15 | $75 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
97 | $23 | $170 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
87 | $2 | $18 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
66 | $19 | $111 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
66 | $18 | $91 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
47 | $4 | $19 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
46 | $9 | $54 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
38 | $24 | $110 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
34 | $84 | $291 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
34 | $1 | $15 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
33 | $14 | $66 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
31 | $128 | $446 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
28 | $1 | $17 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
24 | $131 | $385 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
23 | $15 | $73 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
19 | $41 | $204 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
14 | $36 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
38.6% high complexity
59.6% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,437
Total received (2018-2024)
Avg $1,491/year across 7 years
Top 30% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
62
Companies
596
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,969 (95.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$468 (4.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,524
2023
$1,582
2022
$838
2021
$550
2020
$733
2019
$2,272
2018
$2,938
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$156
PFIZER INC.
$136
Novartis Pharmaceuticals Corporation
$120
Incyte Corporation
$105
Astellas Pharma US Inc
$97
Daiichi Sankyo Inc.
$95
Celgene Corporation
$93
Merck Sharp & Dohme LLC
$80
Regeneron Healthcare Solutions, Inc.
$80
Gilead Sciences, Inc.
$79
Genentech USA, Inc.
$77
Janssen Biotech, Inc.
$57
E.R. Squibb & Sons, L.L.C.
$48
Aveo Pharmaceuticals, Inc.
$45
ABBVIE INC.
$44
SOBI, INC
$41
BeiGene USA, Inc.
$28
ADC Therapeutics America, Inc.
$27
Karyopharm Therapeutics Inc.
$19
Boehringer Ingelheim Pharmaceuticals, Inc.
$18
Myriad Genetic Laboratories, Inc.
$17
Lilly USA, LLC
$16
Pharmacosmos Therapeutics Inc.
$16
EMD Serono, Inc.
$15
Spectrum Pharmaceuticals Inc.
$14
Top 3 companies account for 27.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,053
AstraZeneca Pharmaceuticals LP
$853
Takeda Pharmaceuticals U.S.A., Inc.
$659
Genentech USA, Inc.
$622
Janssen Biotech, Inc.
$619
PFIZER INC.
$598
E.R. Squibb & Sons, L.L.C.
$569
Merck Sharp & Dohme Corporation
$545
Amgen Inc.
$510
Incyte Corporation
$369
Daiichi Sankyo Inc.
$268
Celgene Corporation
$264
Merck Sharp & Dohme LLC
$246
GENZYME CORPORATION
$234
Astellas Pharma US Inc
$193
Clovis Oncology, Inc.
$160
Janssen Pharmaceuticals, Inc
$159
Lilly USA, LLC
$155
Exelixis Inc.
$151
Regeneron Healthcare Solutions, Inc.
$142
Pharmacyclics LLC, An AbbVie Company
$126
Gilead Sciences, Inc.
$122
Eisai Inc.
$118
EMD Serono, Inc.
$109
Ipsen Biopharmaceuticals, Inc
$105
Boehringer Ingelheim Pharmaceuticals, Inc.
$97
Karyopharm Therapeutics Inc.
$86
Seagen Inc.
$84
JAZZ PHARMACEUTICALS INC.
$82
Aveo Pharmaceuticals, Inc.
$70
Alexion Pharmaceuticals, Inc.
$61
TESARO, Inc.
$59
ADC Therapeutics America, Inc.
$59
G1 Therapeutics, Inc.
$59
SOBI, INC
$58
ARRAY BIOPHARMA INC
$56
EISAI INC.
$54
Lexicon Pharmaceuticals, Inc.
$49
BeiGene USA, Inc.
$46
ABBVIE INC.
$44
Jazz Pharmaceuticals Inc.
$39
Puma Biotechnology, Inc.
$38
Blueprint Medicines Corporation
$35
AbbVie Inc.
$32
Taiho Oncology, Inc.
$31
AbbVie, Inc.
$31
AVEO Pharmaceuticals, Inc.
$29
Agios Pharmaceuticals, Inc.
$28
MEDIVATION FIELD SOLUTIONS LLC
$27
Bayer HealthCare Pharmaceuticals Inc.
$26
Seattle Genetics, Inc.
$25
Coherus Biosciences Inc.
$24
CTI BioPharma Corp.
$19
MorphoSys, US Inc.
$18
SERVIER PHARMACEUTICALS LLC
$18
Myriad Genetic Laboratories, Inc.
$17
Rigel Pharmaceuticals, Inc.
$16
Pharmacosmos Therapeutics Inc.
$16
TAIHO ONCOLOGY, INC.
$15
Spectrum Pharmaceuticals Inc.
$14
Adaptive Biotechnologies Corporation
$13
Dova Pharmaceuticals
$12
Top 3 companies account for 24.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aranesp · Avastin · BAVENCIO · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERLEADA · Enhertu · Erivedge · Erleada · FASLODEX · FOTIVDA · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · IRESSA · Imbruvica · Itovebi · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · MYRISK · NINLARO · Nerlynx · Neulasta · Nplate · OPDIVO · OPDUALAG · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PREVNAR 20 · PROMACTA · Perjeta · Pomalyst · REBLOZYL · RETACRIT · ROLVEDON · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Somatuline Depot · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEVIMBRA · TIBSOVO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
7
Per 100K population
10.7
County median income
$64,962
Nearest hospital
BLESSING HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Smith is a mixed practice specialist, with above-average Medicare volume (top 10% in IL), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Smith experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Smith performed 37,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Smith receive payments from pharmaceutical companies?
Yes. Dr. Smith received a total of $10,437 from 62 companies across 596 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Smith's costs compare to other hematology & oncology specialists in Quincy?
Dr. Smith's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Smith) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Quincy
Browse hematology & oncology specialists in Quincy ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology